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SyncopeAbstract Acetylcholinesterase inhibitors are group of drugs commonly used in Alzheimer disease
and have beneﬁcial effects on treatment. Although they have many known side effects, cardiovas-
cular side effects are rarely seen. We present a 84 year old female who was admitted to emergency
service due to repetitive syncope episodes while taking donepezil. Her electrocardiogram showed
QT prolongation and on follow-up a Torsades de Pointes episode occurred. Patient was discharged
with normal corrected QT time after removal of donepezil.
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nd/4.0/).1. Introduction
Donepezil is a widely used Acetylcholinesterase inhibitor
(AChI) for Alzheimer’s disease treatment. It has remedial
effects mainly on the cognitive functions and it increasespatient compliance.1,2 It has gastrointestinal side effects such
as nausea, vomiting, appetite loss, diarrhea albeit its beneﬁcial
effects. Rarely reported cardiac adverse effects were mainly
bradycardia and related syncope.3 We reported a patient tak-
ing donepezil experienced syncope due to QT prolongation
and subsequent Torsades de Pointes (TdP) not related to
bradycardia.
2. Case report
A 84 year old female patient was admitted to emergency
service due to recurrent syncope episodes for two days. She
mentioned palpitations beginning shortly before syncope.
Figure 2 Telemetry revealed Torsades de Pointes and follow-up
rhythm.
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nausea and vomiting. She had been taking regularly donepezil
10 mg for Alzheimer’s disease, ramipril 5 mg for hypertension
and acetylsalicylic acid 100 mg for coronary artery disease.
Her medical history revealed a thorough examination due to
chest pain and syncope three years ago in another hospital.
She had no history of antiarrhythmic drug use, family history
of Long QT syndrome or sudden cardiac death. On admission,
mean arterial pressure was 160/100 mmHg, mean heart rate
was 65 bpm, and pulse oxygen saturation was 95%. ECG
showed atrial ﬁbrillation with deep T wave inversions on pre-
cordial derivations and QTc interval was measured 624 ms
(calculated by Bazett’s formula) (Fig. 1A). Renal function
tests, cardiac biomarkers and electrolytes were normal. Her
carotid and vertebral arterial doppler ultrasonography were
normal. Echocardiography showed normal left ventricular
systolic function, left ventricular hypertrophy, mild mitral and
tricuspid regurgitation. Cranial computed tomography showed
only senile atrophy without any other pathologic signs. She
was hospitalized in coronary care unit. During follow-up a
sudden TdP episode occurred causing hemodynamic instability
(Fig. 2). The rhythm spontaneously returned to her previous
rhythm of atrial ﬁbrillation. We removed donepezil out of
treatment. We infused supplementary potassium and magne-
sium to prevent TdP recurrence. On 4th day, mean heart rate
and QTc interval were measured 60 bpm and 500 ms respec-
tively (Fig. 1B). On 10th day average heart rate and QTc inter-
val were measured 70 bpm and 430 ms respectively (Fig. 1C).
On follow-up there was no bradycardia or another TdP epi-
sode. She was discharged without donepezil. She did not have
complaint of palpitations and syncope during follow-up for
one year. Her ECG showed normal QTc values as well.
We could have reached other hospital’s discharge reports
during outpatient clinic follow-up. At the time of syncope
three years ago, she had been taking donepezil for one year.
Her coronary angiogram revealed 40% stenosis on left ante-
rior descending artery. An electrophysiology study (EPS) was
performed in order to clarify whether syncope was related to
arrhythmia. EPS conﬁrmed prolonged QRS and QT intervalFigure 1 At the time of admission ECG showed (A) atrial
ﬁbrillation and mean heart rate 65 bpm, and QTc interval was 624
msn on admission. (B) On 4th day average heart rate was 60 bpm,
and QTc interval was 500 msn. (C) On 10th day mean heart rate
was 70 bpm, and QTc interval was 430 msn.and revealed normal sinus and atrioventricular node functions.
No arrhythmia was induced with programmed atrial and ven-
tricular stimulation. 3 days after cessation of donepezil QT and
QTc intervals were shortened 440 and 450 ms respectively
(Fig. 3). She was discharged on 7th day of follow-up with a
normal QTc interval and cautioned not to use donepezil three
years ago. After two years of asymptomatic follow-up, another
unaware neurologist prescribed donepezil for worsening of
Alzheimer symptoms. She had been taking donepezil for one
year at the time she was admitted to our emergency service
due to syncope.
3. Discussion
Alzheimer’s disease is the result of decrements in cognitive
and intellectual functions and it causes impairments in mem-
ory, speech, sensation and thinking. Alzheimer drugs are
more widely used owing to accrue of old aged population.
AChIs are a promising drug group that are used for improve-
ment in cognitive functions of Alzheimer patients.4 They inhi-
bit acetylcholine disruption and thus increase intrasynaptic
acetylcholine amount. Increased acetylcholine level also
increases vagal activity via stimulating GABAergic and
glycinergic inhibitory receptors.4,5 It is ineluctable that
enhanced vagal activity affects gastrointestinal and cardiac
functions. Despite their effects on amelioration of cognitive
and intellectual functions, they have common gastrointestinal
side effects and rare but serious cardiac side effects such as
bradycardia, atrioventricular block, syncope and QT interval
prolongation.6 Donepezil is an AChI and used in the treat-
ment of Alzheimer disease.
Long QT syndrome (LQTS) is characterized by prolonga-
tion of the corrected QT (QTc) interval on the surface electro-
cardiogram and is associated with precipitation of torsade de
pointes (TdP) that may cause sudden death.7 It is mainly
separated into acquired and congenital categories according
to underlying etiology. Congenital LQTS was associated
with many different gene mutations.8 Hypomagnesaemia,
hypokalemia and speciﬁc drugs are the causes of acquired
LQTS. Although it is accepted as an acquired syndrome, it
is well known that silent K channel gene mutations could
underlie or at least accompany the pathophysiology.9 The
diagnosis of LQTS is facilitated with a probability score
known as the ‘Schwartz score’ which takes ECG and familial
and clinical features into account.10
In the literature, there are only ﬁve cases reporting QT pro-
longation associated with donepezil use.11–14 Being on 8th and
Figure 3 ECG obtained in another hospital three years ago. Three days after syncope, ECG showed sinus rhythm and QTc interval was
measured 450 msn.
Long QT syndrome and Torsades de Pointes 1999th decades, possessing coronary atherosclerosis and risk fac-
tors, and multidrug usage are prominent and common features
of patients experienced cardiovascular side effects in reported
cases. Three cases experienced TdP. One of the cases with
TdP had bradycardia and the other one had hypokalemia as
a susceptibility factor. QT prolongation in two cases without
TdP was attributed to concomitant benidipine and escitalo-
pram usage with donepezil. We presented a patient experi-
enced recurrent syncope episodes which are related to QT
prolongation. In our case QT interval prolongation was con-
ﬁrmed by EPS. After donepezil usage for one year syncopes
and palpitations suggesting arrhythmias recurred.
Furthermore there was a two year symptom free interval after
removing donepezil out of treatment. This observation sug-
gested that donepezil is the likely cause of symptoms. Our
patient’s Schwartz score was 6, conﬁrming LQTS and suggest-
ing a genetic surveillance. However, further investigation was
not possible because of unavailability of genetic testing. The
Naranjo probability scale conﬁrmed that donepezil was the
probable cause of QT interval prolongation, TdP and syncope
in this patient.15 Although some studies did not ﬁnd associa-
tion of QT prolongation with donepezil, long-term use in a
patient with risk factors including multidrug usage, advanced
age, hypertension and related left ventricular hypertrophy
could make prone to QT prolongation.16 Physicians should
take these factors into account when prescribing donepezil
and should keep in mind that QT prolongation and TdP
may cause syncope apart from bradycardia in a patient taking
AChIs.
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